All In Biotech

Drug Trial Radar · NCT04059913

Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease

A Prospective, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: May 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 318 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

318

Actual

Start

Jun 11, 2019

Primary completion

Nov 19, 2021

Study completion Dec 17, 2021

Sponsor

Lead sponsor
Kyntra BioIndustry
Sponsor type
Industry
First posted
Aug 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center study in dialysis chronic kidney disease (CKD) participants to evaluate the efficacy and relative safety of different dosing regimens of roxadustat over a 36-week treatment period. There are 3 study periods: * Screening Period (up to 4 weeks) * Treatment Period (36 weeks) Part 1: Correction/Conversion Period (Weeks 1-20) Part 2: Hemoglobin (Hb) Maintenance Period (Weeks 21-36) * Follow-up Period (4 weeks)

Conditions

  • CKD Anemia in Dialysis Participants

Interventions

  • RoxadustatDrug

    Roxadustat will be dosed orally per dose and schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 (ESA Naïve): Percentage of Participants who Achieved Hb ≥110 g/L in the First 20 WeeksTime frame: Weeks 1 to 20
  2. Part 1 (ESA Treated): Percentage of Participants who Achieved Mean Hb ≥100 g/L Averaged Over Weeks 17 to 21 VisitsTime frame: Weeks 17 to 21
  3. Part 2: Mean Hb Value Averaged Over Weeks 33 to 37 VisitsTime frame: Weeks 33 to 37

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site

    Beijing, China

  • Investigational Site

    Beijing, China

  • Investigational Site

    Beijing, China

  • Investigational Site

    Shanghai, China

  • Investigational Site

    Tianjin, China

  • Investigational Site

    Hefei, Anhui, China

  • Investigational Site

    Lanzhou, Gansu, China

  • Investigational Site

    Guangzhou, Guangdong, China

  • Investigational Site

    Shenzhen, Guangdong, China

  • Investigational Site

    Nanning, Guangxi, China

  • Investigational Site

    Zhengzhou, Henan, China

  • Investigational Site

    Wuhan, Hubei, China

  • Investigational Site

    Changsha, Hunan, China

  • Investigational Site

    Baotou, Inner Mongolia, China

  • Investigational Site

    Nanjing, Jiangsu, China

  • Investigational Site

    Nanchang, Jiangxi, China

  • Investigational Site

    Changchun, Jilin, China

  • Investigational Site

    Shenyang, Liaoning, China

  • Investigational Site

    Shenyang, Liaoning, China

  • Investigational Site

    Taiyuan, Shanxi, China

  • Investigational Site

    Xi’an, Shanxi, China

  • Investigational Site

    Xi’an, Shanxi, China

  • Investigational Site

    Chengdu, Sichuan, China

  • Investigational Site

    Chengdu, Sichuan, China

  • Investigational Site

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.